Hello, and welcome to the PacBio Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Todd Friedman, Director of Investor Relations. Todd, please go ahead.

Good afternoon, and welcome to PacBio’s fourth quarter 2022 earnings conference call. Earlier today, we issued a press release outlining the financial results we will be discussing on today’s call, a copy of which is on the Investor section of our website, www.pacb.com, or as furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov. With me today are Christian Henry, President and Chief Executive Officer; and Susan Kim, Chief Financial Officer. Before we begin, I would like to remind you that on today’s call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations regarding our Revio Onso system and their commercialization timeframe, the future availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using PacBio products or technology, including our Revio Onso systems. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed, including those inherent in developing and commercializing new products. We refer you to the documents that we file with the SEC, including our most recent forms 10-Q and 10-K and our recent press release to better understand the risks and uncertainties that could cause actual results to differ. We disclaim any obligation to update or revise these forward-looking statements except as required by law. During the call, we will also present certain financial information on a non-GAAP basis. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under US GAAP. Management believes that non-GAAP financial measures, combined with US GAAP financial measures, provide useful information to compare our performance relative to forecasts and strategic plans and benchmark our performance externally against competitors. Reconciliations between historical US GAAP and non-GAAP results are presented in tables within our earnings release. For future periods, we are unable to reconcile the non-GAAP gross margin and non-GAAP operating expenses without unreasonable effort due to the items indicated in our earnings release. In addition, please note that today's call is being recorded and will be available for audio replay on the Investor section of our website shortly after the call. Investors electing to use the audio replay are cautioned that forward-looking statements made on today’s call may differ or change materially after the completion of the live call. Finally, we will be hosting a question-and-answer session after our prepared remarks. We ask that analysts please limit themselves to one question, so that we could accommodate everybody in the queue. And with that, I’ll now turn the call over to Christian.

Thank you, Todd. Good afternoon and welcome to our fourth quarter results and business highlights call. Thanks for joining us today. We have a lot of exciting news to share and I'll kick things off with an update on our performance in the fourth quarter and 2022. I'll then delve into some exciting developments we've seen in the past few months and wrap up with an update on our market segmentation. Susan will then provide a more in-depth look at our financial results and our guidance. But first, a quick recap on revenue. Our most transformative long-read sequencer, Revio, is just a few weeks away from broad commercial availability, which is scheduled for next month. Currently, we have dozens of instruments on the manufacturing floor in our Menlo Park facility. At this point, we don't see any serious supply chain constraints. As a result, I expect that we'll ship at least 25 Revio systems to customers prior to the end of the quarter. We will continue our manufacturing scale-up through the second quarter, and I believe we will be at our planned production rate for 2023 by the end of Q2. This is good news as the Revio platform enables our customers to take on projects in the thousands to tens of thousands of samples. With this scale, we believe Revio will be a game-changer for scientists and clinical researchers. What would have taken years or even decades with long-read sequencing in the past can now be completed in a fraction of the time and cost with the Revio platform. For years, the scientific community has relied on short-read genomes and exomes, yielding valuable insights into the human genome. However, despite millions of short-read genomes being sequenced, much of the genome remains unactionable today, and our understanding of our 20,000 plus genes and their role in driving disease is still quite limited. Further, we now know that phenotype is not solely determined by genes, as mutations in non-coding regions can cause certain cancers. Our understanding of the impact of methylation on genetic disease is in its earliest stages, and we also recognize the importance of both sequence length and accuracy in understanding disorders caused by tandem repeat expansions. It’s clear that to better understand the human genome, researchers must be able to interrogate its full complexity with high accuracy. We expect that sequencing with the Revio platform will provide researchers with the most complete and accurate view of the genome in a single assay. With Revio, researchers will be able to interrogate the genome from telomere to telomere, obtaining phasing information, structural variation, epigenetic profiles, and of course, single nucleotide variants, all at the scale and affordability required for large projects. The early excitement around Revio and the immense possibility for genomics support our belief that we can grow our revenue towards our goal of a compound annual growth rate of 40% to 50% through 2026. As we work to achieve our revenue growth targets, we see 2023 as a year of product transition. We expect many Sequel II and IIe users will migrate over to Revio over the course of the year. These transitions are difficult to precisely predict, and as a result, we may see some temporary variability with respect to consumable revenue. On the instrument side of our business, we expect to see continued strength for Revio throughout the year. Additionally, we do expect to place a modest number of Sequel IIe systems, and of course, also our short-read sequencer remains on track for commercial shipment in Q2 of 2023. As a result, our initial guidance for 2023 is that we expect to achieve between $165 million to $180 million in revenue, which represents growth from 29% to 40%. Now, turning to our results. In the fourth quarter, PacBio achieved revenue of $27.4 million, a 24% decrease compared to the previous year's quarter. The decline in revenue was primarily driven by the announcement of the launch of Revio in the fourth quarter, which impacted orders and shipments for Sequel IIe. We delivered 18 Sequel IIe systems during the fourth quarter, bringing our total installed base to 512 Sequel II and Sequel IIe systems as of December 31. However, what truly sets this past quarter apart is that we received orders for 76 Revio systems, a record-breaking start for a PacBio launch and far surpassing our expectations. We have seen a growing excitement around the potential of Revio, as indicated by the positive feedback we have received from our customers. At the recent AGBT Conference, many customers told us how Revio could help them scale their research and interrogate the genome at unprecedented levels. At the Plant & Genome Conference in January, we saw a deep appreciation for the importance of HiFi sequencing and the enthusiasm for higher output long-read sequencing in the community. We hosted a packed workshop where researchers from Corteva, UCLA, and HudsonAlpha discussed how PacBio sequencing advances their work in agri-genomics, biodiversity, and plant evolution. We are thrilled to announce that the first early access Revio is en route to researchers at the Broad Institute. Over the next few weeks, the team at the Broad Institute will perform their first internal sequencing runs on the platform, and in March, we expect to begin full commercial shipments. The Broad has already ordered 10 Revio systems to scale long-read sequencing for programs like the NIH's All of Us program. To put that in perspective, 10 Revio systems have the equivalent sequencing power of 150 Sequel IIes. We look forward to supporting this project and more population-scale research initiatives to come. While on the topic of All of Us, I wanted to discuss a recent preprint for researchers involved in the program, which highlights the utility of long-read sequencing. The authors noted that HiFi reads produced the most accurate results for both small and large variants, and concluded that 'long reads have widespread value for generating complete and accurate variant calls'. The study also showed that PacBio is best-in-class for calling variants even at lower coverage than other technologies. This supports our belief that even a PacBio genome at 10-fold coverage can be more than sufficient for many research projects. At 10-fold coverage, a Revio can sequence 12 human genomes in 24 hours, or almost 4,000 genomes per year at a list price of approximately $330 per genome with methylation included. The demand for highly accurate reads is increasing, as evidenced by the recognition of long-read sequencing as Nature Methods' method of the year with innovative studies utilizing PacBio's long reads from the Vertebrate Genome Project, Telomere American Consortium, and the Human Pan Genome Reference Consortium. We believe Revio can drive further discovery with its enhanced throughput and cost-effectiveness. Our existing customers have also recognized the potential of Revio to accelerate their research. For example, Mohammed Bin Rashid University of Medicine and Health Sciences purchased Sequel IIe last year and ordered multiple Revios in the fourth quarter to sequence for a very large scale research project in Dubai. The Wellcome Sanger Institute, a longtime user of PacBio for plant and animal research, now plans to increase its use of long reads in human applications, such as single-cell transcriptomics and variant detection with the added power of Revio. Moving on to Onso, our beta program is in full swing at the Broad Institute, Corteva Agriscience, and Weill Cornell, each evaluating how Onso’s extraordinary accuracy can benefit their various genomic applications. Feedback so far has been excellent, with one partner sharing that they are extremely impressed by Onso’s levels of accuracy and another noting how highly accurate reads will be transformative for many genomic applications, including oncology. We're pleased to announce that we're on schedule to begin commercialization of Onso in the second quarter, with a launch specification of 400 to 500 million reads and 200 cycle and 300 cycle kits. The expected specification for accuracy is over 90% of the bases at Q40 Plus and the potential to reach Q50 Plus through approved library preparation. We believe Onso will set a new standard in the industry. The system has a competitive list price of $259,000, with the 300 cycle kit listed at $1,995. We're collaborating with workflow partners across the short-read ecosystem and will provide library prep conversion kits, so that any current short-read assay can move directly onto the Onso platform. Regarding its capabilities, we have validated Onso’s performance through various testing methods, including the SAR-Seq cell-free DNA control with Agilent library prep and capture and our conversion kit. Internal results demonstrate that Onso is two times more sensitive in detecting variant allele frequency of 0.5% and is 1.4 times higher sensitivity, even when applying duplex strategies at four times the coverage with other short-read sequencing technologies. These performance metrics highlight the exceptional value that Onso can bring to the market, offering high accuracy and sensitivity to meet the demands of various genomic applications, including cell-free DNA research. In addition to cell-free DNA, in collaboration with 10x Genomics, Onso achieved 99.8% of the bases at Q30 or better for single-cell RNA reads, showing the potential use of ultra-high accuracy in single-cell workflows. We are dedicated to providing our customers with comprehensive and streamlined solutions for their sequencing workflows. This includes offering a range of tools and workflows that are designed to support their success, from automation to sample preparation and informatics. Our recent initiatives include expanding our MAS-Seq program to support new assays on the Sequel II and IIe and Revio sequencing systems. These kits, which build on the success of last year's MAS-Seq concatenation technology for single-cell isoform sequencing, include 16S and bulk Iso-Seq and will be available later this year. Additionally, our bioinformatics team is continuously improving interpretation tools, such as the recently launched paraphrase tool that helps characterize the dark regions of the genome linked to spinal muscular atrophy. On top of our internally developed products and tools, we're partnering throughout the ecosystem to make it more plug-and-play. As such, we recently introduced the PacBio compatible program designed to make PacBio sequencing more accessible, which includes partners across all ends of the sequencing workflow, from automation and sample and library prep to secondary and tertiary analysis tools. Moving on, I want to share an update on our internal market segmentation from the previous year. In 2022, human genomics was the largest portion of our business, accounting for nearly 40% of our revenue. Customers in this segment include GenDx, who recently ordered a Revio to target difficult-to-sequence genes and sequence human whole genomes for rare diseases, with previously inconclusive results. Radford University has leveraged PacBio technology to make numerous genetic discoveries and plans to ramp up from hundreds to thousands of genomes using Revio. Beyond human applications, we expect Revio to be utilized in applied markets like plant and animal genomics, which made up about 25% of our revenue in 2022. In this market, customers like Corteva Agriscience are utilizing PacBio to study plant genomes and identify microbial infectious diseases that affect these plants, so they can improve crop yields and drive agricultural sustainability. Plant and animal genomics also include research programs like the Darwin Tree of Life Project, which recently celebrated sequencing its 500 HiFi genome. The program aims to sequence 70,000 species of eukaryotic organisms in Britain and Ireland, and we expect Revio to enable the researchers to progress towards this goal. Additionally, infectious disease and microbiology, which represented 20% of our revenue in 2022, includes customers like Bioengineering Lab, who plans to use Revio for metagenomics to discover and characterize communities of microbes for industrial and biomedical applications. About 10% of our 2022 revenue came from oncology applications, with PacBio’s highly accurate long reads allowing researchers to uncover novel isoforms, fusions, and structural variants with exceptional accuracy. Looking ahead, we expect to address more of this large market with Onso's potential for extraordinary sensitivity in liquid biopsy applications. The remaining portion of our revenue comes from other and emerging applications, including gene editing and gene therapy applications. Finally, we are pleased with the support and interest from investors in our equity raise last month. In an upsized offering, we raised $201 million in gross proceeds, which will further bolster our ability to grow our business and drive toward our goal of positive cash flows during 2026. With that, I'd like to turn the call over to Susan to discuss our financials and guidance in more detail.

Thank you, Christian. As discussed, we reported $27.4 million in product, service and other revenue in the fourth quarter of 2022, which represented a decrease of 24% from $36 million in the fourth quarter of 2021. Entrant revenue in the fourth quarter was $6.1 million, a decrease of 62% from $16.2 million in the fourth quarter of 2021. The decline in revenue was primarily driven by the announcement of the launch of Revio in the fourth quarter, which impacted orders and shipments for Sequel IIe. We delivered 18 Sequel IIe systems during Q4, growing the install base to 512 Sequel II and IIe systems as of December 31, 2022. Turning to consumables, revenue of $16.7 million in the fourth quarter grew 11% from $15.0 million in the fourth quarter of last year and was a record for PacBio. Sequel II and IIe consumables represented approximately 94% of our total consumable revenue in the fourth quarter, with the rest from older systems and other consumables. Annualized pull-through per system on the Sequel II and IIe installed base in the fourth quarter was approximately $127,000. We expect Sequel II and IIe pull-through to decline throughout 2023, as we begin shipping Revio and customers transition to the new system. Finally, service and other revenue was $4.6 million in the fourth quarter, compared to $4.8 million in the fourth quarter of 2021. From a regional perspective, America's revenue of $12.0 million declined 36% compared to the fourth quarter of 2021, primarily driven by lower Sequel II and IIe replacements with the recent announcement of the Revio launch. Asia Pacific revenue of $10.2 million grew 23% over the prior year. The region continued to recover with growth from both consumables and Sequel IIe system sales compared to the prior year period. With the launch of Revio, several customers also purchased the Revio-Sequel IIe bundle to progress their HiFi sequencing volume, with plans to further expand upon the receipt of their first Revio. Finally, AMEA revenue of $5.2 million was 43% lower than the prior year period, also primarily driven by lower Sequel II and IIe placements. In addition, currency fluctuations in the pound sterling and euro drove a 7% headwind. In contrast, the region posted another record consumables quarter. Moving down the P&L, GAAP gross profit of $5.1 million in the fourth quarter of 2022 represented a gross margin of 19% compared to a GAAP gross profit of $16.8 million in the fourth quarter of 2021, which represented a gross margin of 47%. Fourth quarter 2022 non-GAAP gross profit of $5.3 million represented a non-GAAP gross margin of 19% compared to a non-GAAP gross profit of $16.9 million or 47% in the fourth quarter of last year. GAAP and non-GAAP gross profit in the fourth quarter reflects loss on purchase commitments and adjustments for excess inventory, totaling approximately $7.1 million, primarily related to a faster than expected ramp in Revio demand, which results in faster than expected decline in Sequel II and IIe demand upon the launch of Revio. GAAP operating expenses were $92.2 million in the fourth quarter of 2022, compared to $81.4 million in the fourth quarter of 2021. Non-GAAP operating expenses were $87.6 million in the fourth quarter 2022, representing a 10% increase for non-GAAP operating expenses of $79.9 million in the fourth quarter of 2021. Increased GAAP and non-GAAP operating expenses primarily reflect higher sales and marketing related expenses. In terms of headcount, we ended the quarter with 769 employees compared to 771 at the end of Q3 2022 and 728 at the end of last year's fourth quarter. Operating expenses in the fourth quarter included total non-cash share-based compensation of $16.8 million compared to $17.5 million in the fourth quarter of last year. GAAP net loss in the fourth quarter of 2022 was $84.4 million or $0.037 per share compared to GAAP net loss of $69.3 million in the fourth quarter of 2021 or $0.31 per share. Non-GAAP net loss was $79.6 million, representing $0.35 per share in the fourth quarter of 2022, compared to a non-GAAP net loss of $66.4 million, representing $0.30 per share in the fourth quarter of 2021. Now turning to our balance sheet, we ended the fourth quarter with $772 million in unrestricted cash and investments, compared with $834 million at the end of the third quarter of 2022. Our ending cash and investments exclude gross proceeds of approximately $201 million resulting from the sale of shares of our common stock in a follow-on public offering in January 2023. Inventory balances increased in the fourth quarter to $50.4 million, representing 1.6 inventory turns, compared with $43.5 million at the end of the third quarter of 2022, representing 1.9 inventory turns. The increase in inventory primarily reflects purchases of Revio and Onso instrument and consumables inventory. Accounts receivable decreased in the fourth quarter to $18.8 million, reflecting a DSO of 70 days compared with $22.8 million at the end of the third quarter of 2022, reflecting a DSO of 71 days. Moving to guidance. For the full year 2023, we expect revenue in the range of $165 million to $180 million, representing a growth rate of approximately 29% to 40% compared to 2022. The lower end of the range assumes that a reduction in Sequel II and IIe consumables from a faster than expected ramp down more than offsets a ramp in Revio consumable revenue later in the year. The high end assumes consumable revenue is flat to slightly higher compared to 2022 and greater Revio shipments. In both high and low ends of the range, we expect service revenue to decline compared to 2022, as customers decommission their Sequel II and IIe. For the first quarter of 2023, we expect to ship at least 25 Revio instruments as we build and ramp manufacturing capacity. We expect manufacturing capacity to scale through the second quarter, reaching our planned production rate for 2023 by the end of Q2. Please note that with the annual guidance in place, we do not expect to share instruments backlog or order numbers on a regular basis going forward. Moving down the P&L, we expect 2023 non-GAAP gross margin to be between 36% and 40%, which will exclude the amortization of intangible assets. Lower margins result from a higher concentration of revenue weighted towards instruments with the early shipments of Revio at lower margin due to the combination of lower ASP from customer loyalty discounts, coupled with higher costs during a new platform launch. We expect margin expansion beyond 2023 and maintain our long-term guidance of 55% to 60% plus in 2026. We expect operating expenses to be in line with long-term guidance and therefore non-GAAP operating expenses will grow less than 5% in 2023 compared to 2022. We expect the weighted average share count for EPS for the full year to be approximately 255 million shares, reflecting the recent sale of common shares and shares expected to be issued as part of the Omniome milestone later this year. With that, I will turn the call back to Christian.

Thank you, Susan. During last month's JPMorgan Healthcare conference, I outlined our strategic goals for this year, focusing on delivering results to our stakeholders. Our first priority is to drive widespread adoption of our Revio sequencer by converting existing Sequel II and IIe customers and attracting new PacBio customers. We're off to a strong start with 76 systems in our backlog as of year-end, and approximately 30% of our sales pipeline consisting of new customers as of year-end. Second, we aim to demonstrate the unparalleled accuracy of Onso in customers' hands and show its ability to transform research in several genomic applications. As discussed, our internal data shows that Onso’s accuracy can detect variants at far greater depth than other short-read systems, and beta partners are sharing that they're having an excellent user experience. Third, we're committed to continuing to develop our long-read sequencing technology, including ultra-high-throughput and benchtop systems, and a next-generation SBB sequencer. This year marks the first step in our journey for offering multiple systems across the sequencing spectrum with Revio and Onso leading the way. Next, we will leverage the current infrastructure to drive towards positive cash flow. As Susan shared with our OpEx guidance, we're going to prioritize and focus on spending on the areas that matter the most. Finally, we plan to expand our partnerships across the ecosystem and workflow to increase customer adoption of SBB and HiFi. With the launch of the PacBio compatible program, we have a framework in place to onboard the best partners in the sequencing workflow. Our long-term goal is to exceed $500 million in revenue in 2026. We believe that 2023 is the start of a multi-year growth story towards achieving this. I look forward to keeping you all updated on our progress throughout the year. And with that, operator, would you please start the Q&A portion of our call.

Yes, of course. We will now begin the question-and-answer session. First question this evening comes from Kyle Mikson with Canaccord. Please go ahead.

Hey, Christian and Susan, thanks for taking the questions.

Hi.

Yes. Hey, so I guess on the guidance. This is kind of the range a lot we’re expecting. Two questions about this, I guess, within my one here. On instruments, does this kind of assume you're streamlining the 25 Revios in the first quarter? I'm just curious if you could kind of talk about what the cadence of the orders and the shipments and the revenue recognition going forward. And maybe like within that, like, beyond the shipment bolus in March and the recommencement of the shipments in maybe May or June, there's going to be probably like an assumption for inventory, instrument terms and the second half. So I'm just curious about that, that's for instruments. On consumables, maybe just pull-through dynamics for Sequel IIe $127k, I think in Q4. I mean, how quickly could that decline? Could that be like $80k to $90k by the end of the year? I think you mentioned, Susan, Revio pull-through could be – you're assuming some consumables there. What are you thinking about it there? Curious about that? Thanks, guys.

Alright. A lot of pack there, Kyle, and thanks. I am back in the saddle. So I'm sorry, I missed everyone at AGPT last week. But let's talk about the guidance a little bit and how we thought about it. We do expect that on a quarter-by-quarter basis, revenues will improve throughout the year. We don't give quarterly guidance on revenue. So I'm not going to speculate other than to say that I do think that what you're going to see us grow over the course of the year and probably going to stop there. With respect to Revio shipments, 25 is really just the start, and we're prepared to produce and ship more than that for a quarter. We're starting at 25 because we want to make sure we have an incredible customer experience with these early shipments as we scale up. So I wouldn't assume that it's a linear kind of outlay quarter after quarter after quarter. But I would say that 25 is a good starting point for us to really get the system out in the field and start to see how it impacts both consumables, with Sequel IIe, but also the utilization of Revio itself. With respect to the pull-through dynamics, as I've said a couple of times, we aren't going to know really what the pull-through dynamics look like for several quarters. The truth is we're not going to try to speculate or guess. What we do know is that some of our largest customers are early adopters of Revio. And so that will impact our assumption that they will use Revio, and they will start to use less Sequel IIe. It may not go totally to zero with those customers, but it will certainly decline as they move to the scale and cost-effectiveness of Revio. That's likely to have an impact and it's likely that it will have an impact on Sequel IIe pull-through probably over the next couple of quarters. But where that ultimately settles out, I think you've quoted $80k to $90k. We don't know and we're not going to make a guess at that today. We’re going to see how this unfolds over the course of the year. I do think Revio utilization will likely grow over the course of the year, particularly as we start to shift to the larger customers first. Then we will start to see some sort of normalization. Based on past experiences, it's probably going to take us three or four quarters to really see where that settles out. So hopefully, Kyle, that answers your questions and gives you a sense of how we're thinking about the guidance with respect to the instruments and consumables.

Yeah. That was great, Christian. I'll hop back in the queue.

The next question is from Julia Qin with JPMorgan. Please go ahead.

Hi, good afternoon. So in terms of the manufacturing capacity for Revio, you said a 25 shipping in Q1 and fully ramped up by Q2. So where do you think the supply will stand at run rate in the second half of the year? And then, in terms of the Revio pull-through ramp, I believe you previously mentioned that you expect a barbell distribution in terms of the customer in a volume. So is it fair to expect that the lower throughput customers will onboard later this year, or do you think that's more of a 2024 and beyond dynamic?

Julia, thank you for the questions and it's good to get to talk to you. You know, first of all, thinking about the run rate on manufacturing, the good news is that we have enough production capacity today to satisfy a very wide range of outcomes with respect to demand. We are going to scale our production and get to our steady state by the end of Q2. But that doesn't mean we couldn't scale further in Q3 or Q4 and beyond. What we're trying to do is not put us in a situation where we produce a lot of instruments at one time and then reduce the steady state. We'd much rather be a little bit more consistent over time because that's how we'll get the best efficiency out of the plant. And that's how we'll get the best, the lowest COGS and improve gross margin. Part of Revio is not only the enablement of this new technology for our customers but also for us to drive our gross margin improvement both through the instrument itself over time and especially because it can be a much higher pull-through instrument, which will drive product mix. When we think about that barbell distribution, as you're talking about with respect to consumables, you're right; typically in these markets, you end up with maybe a bimodal distribution of very high throughput customers with very high utilization and then lower throughput customers. Our expectation is with Revio that the earliest shipments will probably be to the higher throughput and highest throughput, and that'll mostly be through Q1 and even a lot of Q2. But we want to provide this technology to all of our customers, so we're going to try really hard to get some of our lower throughput customers, which we think will be the high throughput customers of tomorrow, the system as soon as we can. Of course, we're going to serve our very large customers and large projects, because they really enable the next sets of large projects to come through to build the business. I would expect to see a broad distribution of customers over the course of 2023 and that will continue on in 2024.

Got you. That's very helpful. And just one follow-up on the Sequel pull-through if I may, I think you mentioned that there might be some near-term volatilities in the Sequel utilization because there is an initial wave of inventory destocking, but then if customers' early orders aren't fulfilled, they might have a rebound in utilization. I'm just curious, has your expected or reasonable expectation of Revio supply constrained in that initial year been communicated to these customers in an attempt to smooth out their inventory management of legacy Sequel II, and how does that tie to the best-case and worst-case scenario of Sequel pull-through that's embedded in your guidance?

Yes. So we have been very clear with our customers, and we are one of the things we are trying to do is, we are laser-focused on our customers. That's one of our core values and helping them understand the timing of when they're going to receive Revio and how they're utilizing Sequel IIe consumables. We really tried working at the grassroots level, with each customer so that they can optimize their experience. Some customers that have ordered, say recently, that it's likely that they're not going to get their Revio for a while, so they're going to continue to run their projects on Sequel IIe. We're going to want to ensure we help them manage that transition. It could have, like I said in my prepared remarks, some variability or volatility around the consumable revenue as we go through this transition. The good news is that by the end of the year, this volatility is likely behind us, and we're scaling our utilization on Revio. We're starting to see the consumable pull-through from Revio. We’re beginning to understand what those numbers look like and have more sense. But the next few quarters, it is going to be transition and we're just managing that the best we can. The good news is, the other piece of good news is that we've done a really good job in producing 25 million smart cells and we're in an excellent inventory position already. If most of you recall, we actually completed the 25 million smart cells over a year ago at this point. So we've got a lot of experience with it. Yields are already coming up in the manufacturing plant. Our ability to supply the market at really any level of demand is already in place effectively, which is super exciting.

The next question comes from Tejas Savant with Morgan Stanley. Please go ahead.

Hey, guys, good evening and Christian, it's good to hear your voice. We missed you at AGBT, especially after the sun went down, as a lot of people told you, I'm sure. On the Revio for us to kick things off, you've got 76 orders in backlog. You're shipping 25 here in essentially a month. You've got the April pause as well, but Mark talked about at AGBT is not particularly impactful from a numbers standpoint. But could we actually see you ship all of the current orders and backlog by the end of the second quarter, or do you see that as more of a third quarter or mid-third quarter situation? And then my second question here is on Onso. So, first, easy one for Susan, what exactly are you baking into the guide for Onso? Perhaps, any color on the number of shipments here in the back half? I think you showed really good data at AGBT. I think it was something like 600 million to, sort of, 730 million reads, higher than your 400 to 500 target range. So what exactly remains to be done there over the next few months other than just incorporating some of the learnings from your beta users?

Yeah. Okay. A lot to unpack there, Tejas. Thank you for the questions. First of all, I want to – you're right. We had 76 orders in backlog at the end of December. But the truth is, we have more orders in backlog than we did at the end of December today. The reason why I start by that is that we expect to continue getting more orders over the course of the year. Shipping the 76 by a certain amount of time, I would expect us to carry backlog for quite a while actually because I do think the order demand is quite substantial. What we’re doing is working to ship the 25, at least 25 units as I said specifically, this quarter to get started. In April, we're still going to be manufacturing systems all through April, so when we say pause, all we're doing is making sure the field is satisfied with how customers are ramping up on Revio. It has nothing to do with anything other than that, and so will it has exactly zero impact on our ability to deliver revenue in Q2. I just want to make that crystal clear because it seems like some analysts have really kind of drilled into that and I don't. What we're focused on is having an incredible launch. This is part of how you plan these things out to do it exceptionally well. I'm not really going to say when the 76 gets all shipped, but I do expect this to run in backlog for several quarters this year. This is partially because I think the order book is going to be very strong all year. What we have left to do with Onso is really in the phase of making sure that the instrument can be produced at scale and making sure that we can ensure the chemistry is hardened so that it can reach a broad diversity of customers. We’re also working to make sure we get production of flow cells right so that we can deliver our orders consistently and at scale. We do still need to do some software work, as there always is. So there’s still a lot to work on, but the good news is you’re seeing the chemistry starting to perform, you’re seeing the densities improving and there’s incredible accuracy even in the hands of our beta customers. So, all those signs are really encouraging for us. It’ll just speak about the ramp, scale, finalizing the development, and taking feedback from those beta customers and integrating it into the product. Part of this is also making sure that that Onso launch doesn’t interfere with the Revio launch too. We want to ensure that we manage both launches exceptionally well because we think both products are critical to pushing the state of the community forward and allowing us to really grow and take a leadership position in this community. Susan, do you want to comment on Onso in the guidance?

Sure. So I think with that backdrop, we are super excited by the positive customer feedback on Onso and customer interest in the revenue Onso bundle. But in terms of the year, this is a Revio year in terms of our guidance. I guess to provide some perspective in terms of Onso, what is baked into our guidance is basically a modest number of Onso shipments in the year, but it's not a material contribution to the overall revenue number as this year again is mostly driven by Revio.

Yeah, particularly most of the growth. Most of the growth, exactly.

The next question comes from Dan Brennan with Cowen. Please go ahead.

Great. Thanks for taking the questions. I guess, maybe I'll stick with one, but I guess a multiple product, if that's easier. In terms of consumable that was really helpful to hear some color in the total guide but how to think about consumables at the high end of the guide? And while I appreciate the Sequel IIe roll-off, it's a hard thing to predict. Can you give us any more color within that guidance range? What are the barriers on Sequel IIe consumable? And then, Christian, certainly can appreciate that the orders didn't stop at year-end. You discussed 76 orders from 43 countries and 30% goes from new customers. That was as of the end of the fourth quarter. Can you just give us some color maybe about how the order book has evolved since early January? And I'll leave it there. Thanks.

Yeah. I mean, I think, we're going to try to stay out of looking at backlogs and order books in the snap, but to color what's happened since year-end. We've had two very, very, very successful conferences, the Plant and Animal Genomes Conference and AGBT. If anything, the funnels are strengthening the perspectives. Lots of customers or many customers have actually run samples inside of our labs now in our applications labs. So, customers are getting more confidence around what we say it is. I think that's exciting. So the funnel continues to strengthen. It is a global funnel, and there are a lot of new customers. It's important for us to show new customers and see these new customers get engaged with the technology. So far, we’ve seen a lot of that internally, and perhaps maybe most interestingly, the scale people are starting to talk about is different than ever before in the history of PacBio. They’re starting to contemplate projects of 10,000 samples, 20,000 sample projects, larger scale, large-scale transcriptomic projects, and large-scale whole genome projects. All of that is extremely encouraging to prove out the thesis that we needed to get to higher throughput and we needed to get to economics that enable scale. We already and continue to do with the best accuracy and as that all-of-us preprint showed, quite frankly, HiFi sequencing right now is the most accurate and most complete sequencer you can get. And so that's all been really well. I know that doesn't help you build your model per se, but anecdotally, it makes us feel a lot better. I didn't understand, Dan, your question really on guidance barriers on Sequel II. Maybe could you ask that question again?

I think Susan talked about consumables at the high end of the guide would be flat to up, but that I presume you’re referring to total consumable, so Revio plus Sequel. I was just trying to clarify that, and if it was, I was just trying to think through on Sequel itself within the guidance any color on how we're thinking about Sequel IIe consumables at the high end and the low end of the guide?

Yeah. Yeah, Susan was talking about the total consumable number, which makes the total number a hard number to predict because you don't know how fast Sequel II is going to decline. You do know that Revio is going to accelerate and it's going to continue to accelerate throughout the year, but we don't know yet how that transpires exactly. And so that's why when we think about our guidance, we have contemplated that volatility in the range of different outcomes. That's probably the easiest way to put it.

The next question comes from David Westenberg with Piper Sandler. Please go ahead.

Hi. Thank you for taking the question. I echo everybody's sentiment when I said, we really missed you at AGBT. So let's start with, I think you've got the number 30% new to PacBio. Would you be willing to discuss whether they might be existing long-read customers using maybe O&T, looking for accuracy at a lower cost or if this would be short-read customers that really are looking for long reads because for all that it offers and the projects that they're looking at? Is there any way to describe that 30% of customers?

I don't have the details in front of me, so I can't provide specifics. However, there have been many discussions, and I want to touch on the second half because I wasn't present at AGBT. At AGBT, several customers expressed their desire to transition to Revio from their current long-read sequencing methods due to the perceived accuracy and completeness. They trust the strength of our platform based on their experience with Sequel IIe. While we have observed this, the majority of the shift will be short-read customers moving to long-reads. It's important to note that nearly every sequencing lab currently has a short-read sequencer, which is the dominant form worldwide. What we are seeing is that labs are introducing Revio machines and gradually shifting projects from short-reads to long-reads, precisely for the advantages of completeness, structural variation, clear phasing without additional techniques, and insights into epigenetics. It's clear that there are substantial benefits to using long-reads over short-reads in most scenarios, and more people are beginning to make that transition. Revio machines will coexist alongside current short-read sequencers, and they will capture increasing amounts of funding across various applications where we possess clear competitive advantages. Now we have the scale and cost structure to support our customers effectively.

The next question comes from Sung Ji Nam with Scotiabank. Please go ahead.

Hi. Thanks for taking my question. I can totally appreciate that this is the year for Revio. But given the really positive feedback on Onso and also the really attractive bundles that you were offering, I was just kind of curious what your thoughts are in terms of the attachment rate, if you will, in the outer years and also in order what would you think might be kind of the biggest barrier in terms of customers really adapting Onso at this point? Are they looking for more data comparing Onso to other short-read platforms?

Yes, I think you're right. There is a lot of excitement about Onso because for the first time in a very long time, there’s significant differentiation in the short-read space with Onso. Customers see that; they see the bundle pricing and offering that we have as something unique and no one else can provide that, and so exactly why our strategy of becoming the only company with highly accurate long- and short-read technologies gives us the ability to talk to every customer in the space and really ask them what questions are they trying to answer and provide them solutions that answer their questions. That’s going to be really powerful not only as we get out of the gate here but over the next several years in particular. What I think customers are going to be excited about is getting Onso into the lab to see what it can do and then watching our ability to increase the power of the technology through increases in density, driving more reads per run, which would create more value than ever before. It’s really that differentiation. I think the barriers today are probably the biggest barriers we have to get the product to market to be maybe a little tongue-in-cheek, but that's really what it is. I think that there is a lot of excitement around the product. We need to finalize the development, make it highly robust, and have an amazing launch and that's really what we're going to do here over the next, as we get Revio out the door and prepare for Onso, then you're going to see us continue to focus over the second half of the year and into next year on how you integrate with bundles, how you increase the performance of both Revio and Onso, and then increase our value to the customers. That’s really the plan of attack here. I'm very enthusiastic about it. I mean, from a guidance perspective, we are taking a modest view because we want to ensure we get this right. We know that there's a lot of choice in the market. We believe we have a highly differentiated offering. But we also want to be practical and responsible about how we give our financial guidance.

The next question comes from John Sourbeer with UBS. Please go ahead.

Hi. Thanks for taking the question here. Maybe just a question for Susan, and on the greater than 25 shipments in the first quarter. Do you think you can recognize those in revenue, or can you remind us how the revenue recognition is on the shipment? And then follow-up, it sounds like the Broad for the Revio has been shipped up the door, have they actually received it and up and running? If so, any early feedback on the installation there and software? Thanks.

Yeah. So John, those will be recognized as revenue because the predominance of our shipments are the prime elements of the instruments delivered to customers is recognized upon delivery. So that is meant for revenue recognition in the quarter.

And then on the Revio going to the Broad, we sent it via truck, so the truck is arriving in the next few days.

Yeah.

And so the truck will arrive and they'll install it next week. They're very capable, so I wouldn't be surprised if before the end of the month, we're starting to see runs come off the machine assuming the installation goes well.

The final question this evening comes from Ross Osborn with Cantor Fitzgerald. Please go ahead.

Hi, thanks for squeezing me in. I know, it's been a long call. So I'm just curious to hear your view on China. You said the borders are opening, but cases increasing with relatively strong instrument demand. Any insight into overall activity would be appreciated.

Right now, overall activity has been pretty good. We had very strong demand for Revio in China. I think that's going to help us with our Chinese revenue in the quarter. You're right, when I give guidance, one of the things I do worry about is how does China play itself out this year because we all – none of us really know how that will completely play itself out. What buoys my confidence is the fact that we have a new product cycle and a lot of enthusiasm and a lot of orders are ready for Revio. That will help. But you're right, potential closures, COVID, those kinds of things. There are still headwinds that we face in the market, and when we were thinking about our guidance, we were trying to think through that. There are still headwinds sitting out there that we're concerned with and watching, but so far, our view on China right now is that we expect it to be operations as normal. We will be shifting some Revio to China this quarter, and that will help get those customers started. But right now, there's nothing extraordinary to report, but we are watching, as I'm sure all of our competitors and peers, how that will unfold over the next several quarters.

This concludes our question-and-answer session. I would like to turn the conference back over to Todd Friedman for any closing remarks.

Thank you all for joining us today. We look forward to connecting with many of you later this quarter at our several industry events and updating you on our progress this year. As a reminder, a replay will be available on our website. And this now concludes our call. Thank you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.